Baird Maintains Outperform on Regenxbio, Raises Price Target to $32
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and raises the price target from $27 to $32.
Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and raises the price target from $27 to $32.